Wegovy as a weight loss medicine: what patients actually want to know

Step 1, Understanding what Wegovy actually does in your body

Semaglutide mimics a hormone your gut already produces after eating. It attaches to GLP-1 receptors in the brain and digestive system, signalling that you are full sooner and keeping food moving through your stomach more slowly. The result for most people is a genuine reduction in appetite rather than a white-knuckle attempt to eat less by willpower.

This mechanism matters for setting realistic expectations. Wegovy is not a metabolism booster or a fat-blocker, it is an appetite regulator. Weight loss happens because you are eating less, not because the medicine burns calories directly. That distinction shapes how you eat alongside it: protein intake, hydration and some form of regular activity all support the process, which is why the licence specifies use alongside a reduced-calorie diet and increased physical activity.

A question our prescribers hear most weeks is whether the medicine "does the work for you". The honest answer is that it removes one of the biggest biological barriers (the hunger that undercuts every diet) but the lifestyle piece still matters for sustaining results long-term. The clinical evidence on semaglutide for weight loss covers this in more detail if you want to read the trial data.

Step 2, How the dose builds, and what the newer 7.2 mg pen changes

Treatment starts at 0.25 mg once a week. Your prescriber then moves you through 0.5 mg, 1.0 mg, and 1.7 mg, roughly one step per month, before reaching the standard maintenance dose of 2.4 mg. The gradual climb exists to help your digestive system adjust and to reduce the nausea that can come with faster escalation.

In April 2026, the MHRA approved a dedicated single-dose 7.2 mg pen, a higher maintenance option for adults with a BMI of 30 or above. Trials at 7.2 mg reported around 20.7% average weight loss over 72 weeks, closing the gap with tirzepatide results. The titration pathway still begins at 0.25 mg; a prescriber decides whether and when 7.2 mg is appropriate for you. If you are curious about how long Wegovy takes to produce visible weight loss, the answer depends partly on which dose you reach and how your body responds to it.

Specific dose and pen availability is always confirmed at your consultation rather than assumed, because supply and clinical suitability both factor in.

Step 3, Who it is licensed for, and what the NICE guidance says

The UK licence covers adults with a BMI of 30 or above, or 27 to 29.9 alongside at least one weight-related condition such as high blood pressure, type 2 diabetes, high cholesterol or obstructive sleep apnoea. Lower thresholds apply for some ethnic backgrounds under UK guidance, your prescriber will factor this in.

NICE recommends semaglutide (TA875) specifically within specialist weight management services, for a maximum of two years, in people with a BMI of 35 or above and at least one weight-related comorbidity. Private treatment through a regulated pharmacy sits outside the NHS commissioning criteria and does not carry the two-year NICE restriction, though a prescriber still reviews your full picture before approving treatment.

Wegovy is not recommended during pregnancy, while breastfeeding, or if you are actively trying to conceive. It is also not licensed for anyone under 18. If you use oral contraceptives, your prescriber can advise on additional precautions, as NHS guidance notes some potential for reduced pill absorption with this class of medicines.

For a broader view of what Wegovy is and how it compares to other options, that page covers the landscape clearly. And if cost is on your mind, the Wegovy pricing page sets out what private treatment typically involves.

Step 4, Side effects to be aware of, and when to seek help

The side-effect profile is led by the digestive system. Nausea is the most commonly reported, followed by vomiting, diarrhoea, constipation and indigestion. Most people find these effects are most pronounced in the first days after a new dose and settle as the body adjusts. If you would like a fuller picture of how Wegovy weight loss works in practice, including what to eat and how to manage early side effects, that page brings it together in one place.

More serious but less common effects include pancreatitis. The MHRA's Drug Safety Update (January 2026) highlighted acute pancreatitis as an infrequent but potentially serious risk with GLP-1 medicines. If you develop severe, persistent stomach pain that spreads to your back, with or without vomiting, seek urgent medical attention rather than waiting to see if it passes.

Gallbladder problems, signs of dehydration from prolonged vomiting or diarrhoea, and allergic reactions are also listed in the patient information leaflet as reasons to contact a healthcare professional promptly. The NHS semaglutide medicines page has the full side-effect listing in plain language, and suspected side effects can be reported via the MHRA Yellow Card scheme.

If you have read this far and want to find out whether Wegovy could suit your circumstances, you can speak to our prescribers through a free consultation, where a GPhC-registered clinician will also help you understand how your starting weight affects what you can expect from Wegovy before any treatment is approved.